Skip to main content

Month: March 2024

Bahr Transportation Transforms Operations with Descartes’ Transportation Management, Freight Visibility and Capacity Sourcing Solutions

ATLANTA and LONDON, March 26, 2024 (GLOBE NEWSWIRE) — Descartes Systems Group (Nasdaq: DSGX) (TSX:DSG), the global leader in uniting logistics-intensive businesses in commerce, announced that Charlotte, NC-based Bahr Transportation, a freight brokerage specializing in the movement of perishable goods across the U.S. and Canada, is using the cloud-based Descartes Aljex™ transportation management system (TMS), together with Descartes MacroPoint™ real-time transportation visibility platform (RTTVP) and automated capacity sourcing solutions. The integrated solutions allow Bahr Transportation to cover more customer freight while providing full visibility across the supply chain to enhance shipper and carrier relationships. “We specialize in refrigerated shipments of temperature-sensitive perishable goods, which means we...

Continue reading

e.GO Announces Nasdaq Delisting Notice

AACHEN, Germany, March 26, 2024 (GLOBE NEWSWIRE) — Next.e.GO N.V. (NASDAQ:EGOX) (“e.GO”) today announced that on March 25, 2024 the Company received a Staff determination letter (the “Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company of the Staff’s determination to delist the Company’s securities because the Company’s securities have had a closing bid price below $0.10 for ten consecutive trading days, which triggers a notice of delisting pursuant to Nasdaq Listing Rule 5810(c)(3)(A)(iii) (the “Low Priced Stocks Rule”). In addition to the $0.10 Rule delisting notice, the Company also currently fails to satisfy the requirement that the closing bid price of its securities remain at $1.00 or higher as required by Nasdaq Listing Rule 5810(c)(3)(A) (the “Minimum Bid Price...

Continue reading

Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Data readout from Phase 3 clinical trial in the People’s Republic of China (“PRC”) evaluating F351 for the treatment of CHB-associated liver fibrosis expected by early 2025 U.S. Phase 2a clinical trial evaluating F351 for the treatment of NASH-associated liver fibrosis planned for 2025 Appointed Dr. Han Ying as Chief Executive Officer Acquired indirect controlling interest in Beijing Continent Pharmaceuticals Co., Ltd. (d/b/a Gyre Pharmaceuticals Co., Ltd) as part of business combination agreement with GNI Cash and cash equivalents totaled $33.5 million as of December 31, 2023 SAN DIEGO, March 26, 2024 (GLOBE NEWSWIRE) — Gyre Therapeutics, Inc. (“Gyre”) (Nasdaq: GYRE), a clinical-stage biotechnology company developing anti-fibrotic therapeutics for a variety of chronic organ diseases, today announced financial results for...

Continue reading

Parsons Continues US Air Force Research and Development Support Through $28 Million Task Order

CHANTILLY, Va., March 26, 2024 (GLOBE NEWSWIRE) — Parsons Corporation (NYSE: PSN) announced today that the company was awarded a $28 million cost-plus-fixed-fee contract to provide intelligence, surveillance, and reconnaissance command and control and space software baselines for the Air Force Research Laboratory’s (AFRL) Global Application Research, Development, Engineering, and Maintenance (GARDEM) program. The contract includes one three-year performance period and extends Parsons’ portfolio of work supporting the Department of Defense (DOD) and Intelligence Community (IC), delivering exquisite software capabilities across the all-domain battlespace. “Parsons delivers value for national security customers like the U.S. Air Force by integrating technologies, transforming data, and customizing site-specific capabilities to meet...

Continue reading

UTStarcom Announces Changes to Its Board of Directors

HANGZHOU, China, March 26, 2024 (GLOBE NEWSWIRE) — UTStarcom (“UT” or the “Company”) (NASDAQ: UTSI), a global telecommunications infrastructure provider, today announced changes to the Board of Directors and appointed Dr. Yong Wang as the Company’s new independent director, effective Mar 21, 2024. Dr. Jintong Lin resigned from the Company’s board of Directors, as well as the chairman of the Company’s Nominating and Corporate Governance Committee, member of Audit Committee and Compensation Committee on Mar 21, 2024, which he had held since September 2019. Dr. Yong Wang was appointed as an independent director of the Company and the positions in various committees vacated by Dr. Lin, effective Mar 21, 2024. Mr. Ning Shan, UTStarcom’s Chairman of Board of Directors, commented, “On behalf of the Company and the board of directors, we...

Continue reading

Valeura Energy Inc.: Fourth Quarter and Year-end 2023 Results

Record Results in 2023 from First Year of Thailand Operations SINGAPORE and CALGARY, Alberta, March 26, 2024 (GLOBE NEWSWIRE) — Valeura Energy Inc. (TSX:VLE, OTCQX:VLERF) (“Valeura” or the “Company”), the upstream oil and gas company with assets in the Gulf of Thailand and the Thrace Basin of Türkiye, reports its financial and operating results for the three month period and year ended December 31, 2023. The complete reporting package for the Company, including the audited financial statements and associated management’s discussion and analysis (“MD&A”) and the 2023 annual information form (“AIF”), are being filed on SEDAR+ at www.sedarplus.ca and posted to the Company’s website at www.valeuraenergy.com.     2023 HighlightsClosed the Mubadala Acquisition(1) for...

Continue reading

Festi hf: Festi acquisition of all shares in Lyfja hf. – Request for conciliation talks with the Icelandic Competition Authority.

Reference is made to Festi’s announcement, published on the 18th of March 2024, regarding the preliminary conclusions in the Icelandic Competition Authority’s investigation into the competitive effects of Festi’s purchase on the entire share capital of Lyfja hf. It is stated therein that the merger will, based on the current state of the investigation, require intervention by the Icelandic Competition Authority. Festi has now submitted a response to the Icelandic Competition Authority‘s preliminary conclusions where Festi‘s arguments and proposals for remedies are presented. The response formally requests a conciliation talks with the Icelandic Competition Authority on possible remedies associated with the aquisition. Festi‘s request is now under evaluation by the Icelandic Competition Authority. Accordingly, the Competition Authority’s...

Continue reading

The results of business activity of ŽEMAITIJOS PIENAS, AB group in 2023, excluding audit

In 2023, consolidated turnover (excluding audit) of ŽEMAITIJOS PIENAS, AB group amounts to 278 million EUR that, if to be compared with the year 2022, has increased by 5,55 %.            Net profit (as without audit) of ŽEMAITIJOS PIENAS, AB group in the year 2023, makes 7,7 % of the turnover.The person authorized to provide additional information: Arnas MatuzasHead of LegalE-mail: a.matuzas@zpienas.lt

Continue reading

Kvika banki hf.: Announcement regarding reduction in share capital

At Kvika’s AGM held on 21 March 2024 the meeting approved to reduce the company’s share capital by ISK 58,952,375 nominal value, or the equivalent of 58,952,375 shares, from ISK 4,781.025,715 to ISK 4,722,073,340 nominal value, by cancelling own shares held by the company in the said amount. These are shares that the company purchased under a formal buy-back programme in 2023. The share capital reduction has now been registed by the register of undertakings of the Directorate of internal Revenue and the share capital amounts to nominal value of ISK 4,722,073,340. Following the reduction the bank holds no own shares. For further information please contact Magnús Þór Gylfason, Director of Communications and Stakeholder Relations, at magnus.gylfason@kvika.is

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.